Ultragenyx Pharmaceutical Inc. (RARE)
Healthcare
- Fundamental
- 3
- Sentiment
- 3
- Technical
- 3
Buy limit 15.90 (pullback_to_support): RARE is retracing to the Nov 13 low 15.85 / EMA21 16.14 zone inside a recovery base above a rising SMA50 (15.29) with MACD still positive; stop 15.04 (1.0xATR Change-A floor, beneath the Nov 6 leg low 15.12), targets 17.62 / 18.91, R/R 2.00.
Company overview
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company focused on developing treatments for rare and ultra-rare genetic diseases. It markets several biologic products, including Crysvita, Mepsevii, Dojolvi, and Evkeeza, and has a pipeline of investigational therapies. The company operates globally and collaborates with various partners to advance its research.
Fundamental
fairUltragenyx has a growing revenue base but remains deeply loss-making with significant obligations.
Commercial-stage rare-disease biotech with roughly $730 million of trailing revenue growing double digits at an 83% gross margin, an improving cash-burn trajectory and about $750 million of pro-forma liquidity after post-quarter PRV sales — but still deeply loss-making, equity-negative, encumbered by $1.19 billion of royalty-monetization obligations, and dependent on a 2027 profitability plan that has yet to be proven. Mixed fundamentals with elevated but not imminent risk.
Sentiment
fairSentiment is balanced with no immediate catalysts and a clean red-flag screen.
Two actionable catalysts point opposite ways inside the window: the 2026-11-03 Q3 print (bearish, announced — revenue of $173.0M against a $182.5M FactSet estimate, shares down pre-bell, and a 20% workforce reduction bundled in) against the 2026-11-06 UK MHRA acceptance of the UX111 MPS IIIA MAA (bullish, regulator_confirmed). The sentiment delta is determinate but flat-to-soft (+0.089 baseline → −0.040 on the deeper 8-item scoring sample) and retail is unmeasurable, and while no severe flag fired, the conflicting-catalyst moderate red-flag cap applies, holding the read to a mixed/forming setup with no forward-dated driver inside 30 days.
Technical
fairRARE is retracing within a recovery base, with MACD still positive and a rising SMA50.
Mixed-to-constructive pullback chart. RARE at 16.08 sits above a rising SMA50 (15.29) and above the 14.4-15.5 September-October base it broke out of on the Nov 3-4 earnings move to 17.67, with MACD still above zero (line 0.04, signal 0.00, histogram +0.04) and the stock 26% off its 12.73 panic low. Against that: price is below SMA20 (16.21), EMA9 (16.24) and EMA21 (16.14) and far below SMA200 (22.53); RSI14 49.12 is neutral, ADX14 16.08 shows no trend, the MACD histogram has faded from +0.27 (Nov 2) to +0.04, and the last three closes stepped down (16.70, 16.27, 16.08) on light volume. ATR14 0.86 is 5.35% of price with StdDev20 0.54. Net read: a pullback inside a recovering base rather than a fresh breakout, so the trade is expressed as a pullback_to_support limit at 15.90 with a 1.0xATR structure stop, not as a momentum stop.
You’re looking at 2026-11-14 — more than 2 trading days ago.
Subscribers saw this then, and see today’s score, verdict and trade plan now.
More Healthcare
Not financial advice. For informational and educational purposes only.

